New helix-shaped molecules to block cancer-driving Wnt signals

Targeting Wnt signaling pathway

NIH-funded research University of South Florida · NIH-11308646

Engineered helix-like molecules aim to block protein interactions that activate Wnt/β-catenin signaling in cancers.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of South Florida NIH-funded
Lab location1 site (Tampa, United States)
Project IDNIH-11308646 on NIH RePORTER

What this research studies

Researchers are designing novel helix-shaped, peptide-like molecules called sulfono-γ-AApeptides to mimic protein α-helices and disrupt BCL9/β-catenin and TCF/β-catenin interactions. In the lab they will test these compounds in cellular and 3-D cell models to see if they shut down Wnt signaling and trigger cancer cell death. Promising compounds will be optimized for stability and cell entry and may be tested in animal models before any human testing. The overall aim is to create drug candidates that could eventually be tested in patients with cancers driven by abnormal Wnt/β-catenin activity.

Who could benefit from this research

Good fit: Patients with cancers known to involve Wnt/β-catenin signaling—such as some colorectal cancers and certain B‑cell lymphomas—would be the most likely candidates for future trials.

Not a fit: People whose tumors are not driven by Wnt/β‑catenin signaling or individuals without cancer are unlikely to benefit from this approach.

Why it matters

Potential benefit: If successful, this work could produce a new class of anti-cancer drugs that slow or stop tumors driven by abnormal Wnt/β-catenin signaling.

How similar studies have performed: Related helical peptidomimetics have shown promise in lab models, but using sulfono-γ-AApeptides to block these specific β‑catenin protein interactions is a novel and largely untested strategy.

Where this research is happening

Tampa, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.